Edwards Lifesciences (EW) Stock Forecast & Price Target

$71.55 +0.28 (+0.39%)

(As of 04:28 PM ET)

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 26 Analyst Ratings

Sell
0

Hold
16

Buy
10

Based on 26 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 26 analysts, 16 have given a hold rating, and 10 have given a buy rating for EW.

Consensus Price Target

$75.67
5.75% Upside

According to the 26 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $75.67. The highest price target for EW is $105.00, while the lowest price target for EW is $57.00. The average price target represents a forecasted upside of 5.75% from the current price of $71.55.

Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

EW Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)
Hold	16 Hold rating(s)	14 Hold rating(s)	13 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$75.67	$75.67	$82.10	$84.29
Forecasted Upside	5.75% Upside	9.06% Upside	19.57% Upside	25.51% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Hold

DeFi Coin on Verge of Breakout! (Ad)

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Edwards Lifesciences Stock vs. The Competition

Type	Edwards Lifesciences	Medical Companies	S&P 500
Consensus Rating Score	2.38	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	5.68% Upside	24,609.58% Upside	6.90% Upside
News Sentiment Rating	Neutral News See Recent EW News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/30/2024	Daiwa America 0 of 5 stars	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/28/2024	Sanford C. Bernstein 3 of 5 stars	L. Hambright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
10/25/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Hold ➝ Hold	$66.00 ➝ $63.00	-10.22%
10/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$72.00 ➝ $78.00	+13.04%
10/25/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$73.00 ➝ $70.00	+1.45%
10/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$71.00 ➝ $70.00	+1.67%
DeFi Coin on Verge of Breakout! (Ad) The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late!
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$73.00 ➝ $68.00	-3.29%
10/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight	$70.00	+2.55%
10/8/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$85.00 ➝ $75.00	+9.41%
10/1/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$83.00 ➝ $77.00	+17.36%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	In-Line ➝ In-Line	$76.00 ➝ $70.00	+6.69%
9/18/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$85.00 ➝ $70.00	+4.14%
9/12/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$90.00 ➝ $90.00	+34.71%
9/10/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$90.00 ➝ $75.00	+12.66%
9/9/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$90.00 ➝ $80.00	+21.34%
9/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$90.00 ➝ $80.00	+19.47%
7/31/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform
7/29/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
7/26/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$107.00 ➝ $91.00	+44.72%
7/25/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Jennings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $70.00	+14.27%
7/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$103.00 ➝ $85.00	+34.60%
7/25/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$85.00 ➝ $70.00	+3.61%
7/25/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$105.00 ➝ $75.00	-13.74%
4/11/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$95.00 ➝ $105.00	+14.78%
3/26/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Mixed ➝ Positive
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$75.00	+4.90%
6/27/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
2/6/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:15 PM ET.

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 25, 2024. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

The current stock price is $70.48, which reflects a recent trading increase of 0.1%. This price point may present a buying opportunity for investors looking to enter at a favorable level.
Edwards Lifesciences Co. has shown a strong revenue growth of 8.9% year-over-year, indicating robust demand for its products and a solid business model.
Institutional investors and hedge funds own 79.46% of the company's stock, suggesting strong confidence from major financial players in the company's future performance.
The company reported a net margin of 70.82%, which is significantly high and indicates effective cost management and profitability, making it an attractive investment.
Recent upgrades from analysts, including a shift to an "outperform" rating by Daiwa Capital Markets, suggest positive sentiment and potential for stock price appreciation.

Edwards Lifesciences
Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

Analysts have lowered their price targets, with UBS Group reducing their target from $90.00 to $75.00, indicating a potential decrease in expected future performance.
The company missed revenue expectations in its latest earnings report, generating $1.35 billion against an expectation of $1.57 billion, which may raise concerns about future growth prospects.
Insider selling activity has been noted, with insiders selling 40,000 shares valued at $2,657,000, which could signal a lack of confidence in the stock's short-term performance.
Despite a high net margin, the price-to-earnings (PE) ratio of 10.17 may suggest that the stock is overvalued compared to its earnings, which could deter some investors.
Recent downgrades from firms like Jefferies Financial Group, which lowered their rating from "buy" to "hold," may indicate a cautious outlook on the stock's performance moving forward.

EW Forecast - Frequently Asked Questions

: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $75.67, with a high forecast of $105.00 and a low forecast of $57.00.
: 26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 16 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
: According to analysts, Edwards Lifesciences's stock has a predicted upside of 5.75% based on their 12-month stock forecasts.
: Over the previous 90 days, Edwards Lifesciences's stock had 2 downgrades and 1 upgrade by analysts.
: Edwards Lifesciences has been rated by research analysts at Barclays, Canaccord Genuity Group, Citigroup, Daiwa America, Evercore ISI, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Edwards Lifesciences less than other "medical" companies. The consensus rating for Edwards Lifesciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EW compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

DeFi Coin on Verge of Breakout! (Ad)

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!

This page (NYSE:EW) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edwards Lifesciences (EW) Stock Forecast & Price Target